Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.
Most grade II and grade III gliomas, as well as the secondary glioblastomas that arise from these tumors, possess point mutations that affect the substrate binding site of isocitrate dehydrogenase. These mutations are essentially unique to gliomas, seem to represent an early step in gliomagenesis, and confer a favorable prognosis.
Schiff
David
D
University of Virginia Neuro-Oncology Center, Charlottesville, VA 22908-0432, USA. davidschiff@virginia.edu
Purow
Benjamin W
BW
D001932:Brain Neoplasms / Q000235:genetics*; D005910:Glioma / Q000235:genetics*; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics*; D009154:Mutation / Q000235:genetics*
D007521:Isocitrate Dehydrogenase